Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adipose Tissue | 9 | 2025 | 295 | 4.170 |
Why?
|
| Tissue Expansion | 8 | 2020 | 24 | 2.820 |
Why?
|
| Neovascularization, Physiologic | 6 | 2019 | 104 | 2.030 |
Why?
|
| Tissue Engineering | 6 | 2020 | 141 | 1.870 |
Why?
|
| Surgical Flaps | 7 | 2019 | 117 | 1.680 |
Why?
|
| Regeneration | 4 | 2025 | 95 | 1.660 |
Why?
|
| Tissue Scaffolds | 7 | 2025 | 84 | 1.370 |
Why?
|
| Adipogenesis | 4 | 2019 | 79 | 1.320 |
Why?
|
| Graft Survival | 4 | 2019 | 289 | 1.260 |
Why?
|
| Abdominoplasty | 2 | 2020 | 3 | 1.260 |
Why?
|
| Ischemic Preconditioning | 2 | 2019 | 8 | 1.220 |
Why?
|
| Mammaplasty | 4 | 2022 | 48 | 1.090 |
Why?
|
| Extracellular Matrix | 4 | 2025 | 139 | 1.050 |
Why?
|
| Wound Healing | 8 | 2025 | 189 | 1.020 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2020 | 199 | 0.960 |
Why?
|
| Skin Transplantation | 6 | 2019 | 154 | 0.950 |
Why?
|
| Soft Tissue Injuries | 1 | 2025 | 21 | 0.890 |
Why?
|
| Guided Tissue Regeneration | 2 | 2014 | 4 | 0.860 |
Why?
|
| Endothelial Cells | 4 | 2019 | 187 | 0.840 |
Why?
|
| Surgical Wound | 2 | 2020 | 10 | 0.810 |
Why?
|
| Animals | 27 | 2025 | 20660 | 0.790 |
Why?
|
| Subcutaneous Fat | 3 | 2019 | 47 | 0.740 |
Why?
|
| Tissue Expansion Devices | 2 | 2019 | 17 | 0.730 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 115 | 0.710 |
Why?
|
| Perforator Flap | 1 | 2020 | 2 | 0.690 |
Why?
|
| Skin, Artificial | 4 | 2017 | 7 | 0.680 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 19 | 0.680 |
Why?
|
| Facial Injuries | 3 | 2019 | 14 | 0.680 |
Why?
|
| Abdominal Wall | 2 | 2018 | 23 | 0.680 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2018 | 12 | 0.670 |
Why?
|
| Frailty | 1 | 2022 | 130 | 0.660 |
Why?
|
| Muscle Development | 1 | 2020 | 54 | 0.650 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2019 | 6 | 0.640 |
Why?
|
| Adiposity | 1 | 2020 | 84 | 0.630 |
Why?
|
| Hyperemia | 1 | 2019 | 13 | 0.630 |
Why?
|
| Angiotensin II | 1 | 2019 | 25 | 0.630 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 1 | 2019 | 1 | 0.620 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 1 | 0.620 |
Why?
|
| Adipocytes | 5 | 2025 | 268 | 0.620 |
Why?
|
| Ischemic Postconditioning | 1 | 2019 | 3 | 0.610 |
Why?
|
| Reperfusion Injury | 1 | 2019 | 53 | 0.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 697 | 0.580 |
Why?
|
| Rats | 7 | 2020 | 1980 | 0.570 |
Why?
|
| Perfusion | 1 | 2018 | 72 | 0.570 |
Why?
|
| Surgeons | 1 | 2020 | 183 | 0.550 |
Why?
|
| Bariatric Surgery | 1 | 2018 | 61 | 0.550 |
Why?
|
| Facial Neoplasms | 2 | 2014 | 7 | 0.540 |
Why?
|
| Facial Transplantation | 1 | 2017 | 8 | 0.540 |
Why?
|
| Models, Animal | 3 | 2017 | 235 | 0.530 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 98 | 0.520 |
Why?
|
| Skin Neoplasms | 4 | 2014 | 412 | 0.510 |
Why?
|
| Collagen | 2 | 2017 | 123 | 0.500 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 2187 | 0.490 |
Why?
|
| Necrosis | 4 | 2020 | 143 | 0.480 |
Why?
|
| Transplantation, Homologous | 5 | 2019 | 245 | 0.480 |
Why?
|
| Postoperative Complications | 3 | 2022 | 1308 | 0.480 |
Why?
|
| Mice | 15 | 2020 | 10844 | 0.480 |
Why?
|
| Dermatofibrosarcoma | 1 | 2014 | 1 | 0.450 |
Why?
|
| Humans | 38 | 2025 | 63446 | 0.440 |
Why?
|
| Regenerative Medicine | 1 | 2013 | 20 | 0.410 |
Why?
|
| Internship and Residency | 1 | 2021 | 808 | 0.400 |
Why?
|
| Median Neuropathy | 1 | 2012 | 1 | 0.400 |
Why?
|
| Lipomatosis | 1 | 2012 | 8 | 0.400 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 11 | 0.390 |
Why?
|
| Replantation | 1 | 2012 | 12 | 0.390 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2012 | 39 | 0.390 |
Why?
|
| Amputation, Traumatic | 1 | 2012 | 11 | 0.380 |
Why?
|
| Thumb | 1 | 2012 | 27 | 0.380 |
Why?
|
| Limb Salvage | 1 | 2012 | 70 | 0.370 |
Why?
|
| Female | 20 | 2023 | 32878 | 0.340 |
Why?
|
| Robotics | 3 | 2016 | 87 | 0.320 |
Why?
|
| Diabetic Foot | 2 | 2023 | 12 | 0.300 |
Why?
|
| Prostheses and Implants | 3 | 2014 | 71 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 3 | 2020 | 140 | 0.290 |
Why?
|
| Suction | 2 | 2018 | 36 | 0.290 |
Why?
|
| Burns | 2 | 2019 | 41 | 0.280 |
Why?
|
| Fibrosis | 2 | 2019 | 160 | 0.270 |
Why?
|
| MicroRNAs | 3 | 2019 | 687 | 0.270 |
Why?
|
| Transplantation, Autologous | 2 | 2025 | 127 | 0.260 |
Why?
|
| Hand | 3 | 2016 | 74 | 0.250 |
Why?
|
| Genetic Therapy | 1 | 2013 | 791 | 0.250 |
Why?
|
| Artificial Limbs | 2 | 2016 | 5 | 0.240 |
Why?
|
| Random Allocation | 4 | 2019 | 199 | 0.240 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6661 | 0.240 |
Why?
|
| Risk Assessment | 3 | 2022 | 2079 | 0.220 |
Why?
|
| Mastectomy, Segmental | 2 | 2015 | 46 | 0.210 |
Why?
|
| Hyaluronic Acid | 2 | 2017 | 67 | 0.210 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 7 | 0.200 |
Why?
|
| Diabetic Nephropathies | 1 | 2023 | 37 | 0.190 |
Why?
|
| Scalp | 2 | 2013 | 29 | 0.190 |
Why?
|
| Diabetic Retinopathy | 1 | 2023 | 53 | 0.190 |
Why?
|
| Hair | 2 | 2013 | 83 | 0.180 |
Why?
|
| Male | 19 | 2023 | 29889 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2023 | 2570 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 2 | 2013 | 168 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2020 | 10 | 0.170 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2020 | 42 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2023 | 2458 | 0.170 |
Why?
|
| Allografts | 1 | 2020 | 46 | 0.170 |
Why?
|
| Time Factors | 2 | 2019 | 3768 | 0.160 |
Why?
|
| Angiography | 1 | 2020 | 153 | 0.160 |
Why?
|
| Cell Extracts | 1 | 2020 | 25 | 0.160 |
Why?
|
| Dermis | 2 | 2017 | 18 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 259 | 0.160 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2019 | 2 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2021 | 147 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 22 | 0.160 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 525 | 0.160 |
Why?
|
| Epigastric Arteries | 1 | 2019 | 6 | 0.160 |
Why?
|
| Iloprost | 1 | 2019 | 3 | 0.160 |
Why?
|
| Rodentia | 1 | 2019 | 22 | 0.160 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2019 | 22 | 0.150 |
Why?
|
| Adult | 10 | 2023 | 16823 | 0.150 |
Why?
|
| Cicatrix | 1 | 2019 | 61 | 0.150 |
Why?
|
| Tissue Transplantation | 1 | 2019 | 9 | 0.150 |
Why?
|
| Neck Injuries | 1 | 2019 | 20 | 0.150 |
Why?
|
| Gelatin | 1 | 2019 | 30 | 0.150 |
Why?
|
| Skin | 2 | 2019 | 373 | 0.150 |
Why?
|
| Embryonic Stem Cells | 1 | 2020 | 157 | 0.150 |
Why?
|
| Breast Implantation | 1 | 2018 | 6 | 0.150 |
Why?
|
| Exhalation | 1 | 2018 | 15 | 0.150 |
Why?
|
| Inhalation | 1 | 2018 | 12 | 0.150 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 26 | 0.150 |
Why?
|
| Biomimetic Materials | 1 | 2019 | 37 | 0.150 |
Why?
|
| Mice, Obese | 1 | 2018 | 80 | 0.150 |
Why?
|
| Body Contouring | 1 | 2018 | 1 | 0.150 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 189 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2018 | 137 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2019 | 56 | 0.150 |
Why?
|
| Mice, Nude | 1 | 2019 | 277 | 0.140 |
Why?
|
| Middle Aged | 10 | 2023 | 17615 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 149 | 0.140 |
Why?
|
| Reference Values | 1 | 2019 | 331 | 0.140 |
Why?
|
| Electromyography | 2 | 2016 | 96 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 207 | 0.140 |
Why?
|
| Wounds and Injuries | 3 | 2017 | 246 | 0.140 |
Why?
|
| France | 1 | 2017 | 14 | 0.130 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 14 | 0.130 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 13 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 115 | 0.130 |
Why?
|
| Cryogels | 1 | 2017 | 1 | 0.130 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 19 | 0.130 |
Why?
|
| Ischemia | 1 | 2019 | 205 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2017 | 50 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2019 | 484 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2017 | 107 | 0.130 |
Why?
|
| Hypoxia | 1 | 2017 | 115 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2018 | 150 | 0.130 |
Why?
|
| Mice, SCID | 1 | 2017 | 519 | 0.130 |
Why?
|
| Facial Nerve Injuries | 1 | 2016 | 4 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 284 | 0.130 |
Why?
|
| Materials Testing | 1 | 2017 | 85 | 0.130 |
Why?
|
| Smad1 Protein | 1 | 2016 | 5 | 0.120 |
Why?
|
| Nerve Regeneration | 1 | 2016 | 35 | 0.120 |
Why?
|
| Forearm | 1 | 2016 | 22 | 0.120 |
Why?
|
| Stromal Cells | 1 | 2016 | 68 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 3396 | 0.120 |
Why?
|
| Amputees | 1 | 2015 | 3 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2017 | 293 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 1198 | 0.120 |
Why?
|
| Incidence | 2 | 2017 | 1377 | 0.120 |
Why?
|
| Burns, Electric | 1 | 2015 | 4 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1119 | 0.120 |
Why?
|
| Mouth | 1 | 2015 | 33 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 109 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 325 | 0.110 |
Why?
|
| Movement | 1 | 2015 | 156 | 0.110 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 144 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 264 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2019 | 3035 | 0.110 |
Why?
|
| Fascia Lata | 1 | 2013 | 2 | 0.110 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2013 | 2 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2575 | 0.110 |
Why?
|
| Charities | 1 | 2013 | 3 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 770 | 0.100 |
Why?
|
| Volunteers | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1353 | 0.100 |
Why?
|
| Motor Activity | 1 | 2016 | 346 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2019 | 5680 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2680 | 0.100 |
Why?
|
| Developing Countries | 1 | 2013 | 94 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 373 | 0.100 |
Why?
|
| Risk Factors | 1 | 2022 | 5353 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2019 | 213 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 338 | 0.090 |
Why?
|
| Ear Auricle | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ear Neoplasms | 1 | 2011 | 6 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1147 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 741 | 0.090 |
Why?
|
| Quality of Life | 1 | 2019 | 1228 | 0.090 |
Why?
|
| Osteoarthritis | 1 | 2013 | 143 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 293 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 16 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 67 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 321 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 345 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 337 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 331 | 0.070 |
Why?
|
| United States | 1 | 2021 | 7842 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 1990 | 0.060 |
Why?
|
| Mice, Hairless | 2 | 2017 | 19 | 0.060 |
Why?
|
| Rats, Inbred Lew | 2 | 2017 | 106 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 453 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 3293 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2019 | 988 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1147 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2023 | 28 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2020 | 110 | 0.040 |
Why?
|
| Infant | 2 | 2015 | 1645 | 0.040 |
Why?
|
| Physical Appearance, Body | 1 | 2019 | 1 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 150 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 39 | 0.040 |
Why?
|
| Esthetics | 1 | 2018 | 19 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 170 | 0.040 |
Why?
|
| Respiration | 1 | 2018 | 89 | 0.040 |
Why?
|
| China | 1 | 2018 | 162 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 240 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 283 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 198 | 0.030 |
Why?
|
| Survivors | 1 | 2019 | 171 | 0.030 |
Why?
|
| Transillumination | 1 | 2017 | 2 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 153 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 193 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 618 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2017 | 40 | 0.030 |
Why?
|
| Porosity | 1 | 2017 | 39 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 85 | 0.030 |
Why?
|
| Breast | 1 | 2018 | 183 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 936 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 207 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 1277 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 937 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2016 | 109 | 0.030 |
Why?
|
| Phantom Limb | 1 | 2016 | 1 | 0.030 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Re-Epithelialization | 1 | 2016 | 4 | 0.030 |
Why?
|
| Aged | 4 | 2013 | 14449 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 525 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Mast Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 433 | 0.030 |
Why?
|
| Cheek | 1 | 2015 | 5 | 0.030 |
Why?
|
| Gingiva | 1 | 2015 | 8 | 0.030 |
Why?
|
| Tongue | 1 | 2015 | 15 | 0.030 |
Why?
|
| Lip | 1 | 2015 | 12 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 608 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 612 | 0.030 |
Why?
|
| Speech | 1 | 2015 | 63 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2040 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 664 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1094 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2016 | 394 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2020 | 795 | 0.030 |
Why?
|
| Altruism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 177 | 0.030 |
Why?
|
| Fund Raising | 1 | 2013 | 7 | 0.030 |
Why?
|
| Surgical Mesh | 1 | 2013 | 59 | 0.030 |
Why?
|
| Italy | 1 | 2013 | 66 | 0.030 |
Why?
|
| Glucose | 1 | 2016 | 467 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 5465 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 41 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 873 | 0.020 |
Why?
|
| Thorax | 1 | 2011 | 34 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 242 | 0.020 |
Why?
|
| Viscosupplements | 1 | 2011 | 14 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 278 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 393 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 509 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Macrophages | 1 | 2016 | 1039 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1003 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1617 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4694 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1748 | 0.020 |
Why?
|